LIfT BioSciences appoints new CSO

LIfT BioSciences has named Dr Mark Exley as chief scientific officer as it prepares for clinical trials of its first-in-class neutrophil immuno-therapy.

A translational immunologist with more than 30 years of experience, Mark has led R&D projects from discovery through to late-stage clinical trials across both biotech and academia.

He most recently served as chief scientific officer at Imvax Inc and previously held senior roles at MiNK Therapeutics and NKT Therapeutics. 

Mark has also worked with biotechs and venture capital firms including Abingworth and retains academic ties with Harvard Medical School and the University of Manchester.

His appointment follows LIfT’s recent donor access deal with Gift of Life Biologics, further strengthening its plans to tackle treatment-resistant solid tumours.

Mark said: “LIfT’s first-in-class cell therapy offers a novel approach to solid tumour treatment, harnessing the largely untapped power of neutrophils to prevent tumour escape and relapse. 

“The company’s preclinical data is compelling, and I look forward to collaborating with the team and applying my R&D expertise to advance N-LIfT through clinical development, bringing us a step closer to making this transformative therapy available to patients in need.”

Alex Blyth, chief executive officer of LIfT BioSciences, added: “I am delighted to announce the appointment of Mark as our new chief scientific officer. 

“He joins LIfT at an exciting time as we prepare to progress our proprietary Neutrophil-based Leukocyte Infusion Therapy (N-LIfT) platform into the clinic. 

“His wealth of experience in cell therapies and clinical trial design will prove invaluable as we enter this next significant stage of development.”

Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →